Cancer drug development has shifted in recent years as traditional chemotherapies give way to targeted therapies and therapeutic antibodies.
We'll discuss the challenges, opportunities and value that a patient-centric model presents for drug development.
Does big pharma give up on its compounds too fast during clinical trials?
It was another busy week for pharma, tech and smart data news. Catch up below, and stay in touch with us all week on Twitter and LinkedIn.